Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3GNRHRMPLPDE3APDE3BPDE4APDE4BPDE4CPDE4DPPARASLC5A2
The experimentally established mechanism targets of Choline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.40 |
| ▸ | PGK1 | P00558 | 1/20 | 0.39 |
| ▸ | PGK2 | P07205 | 1/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.38 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.38 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.38 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.38 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | PGD | P52209 | 3/20 | 0.37 |
| ▸ | MPI | P34949 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Choline SCHEMBL29876695 | 1.00 | SMN1; SMN2 (0.58) | SMN1; SMN2LPAR5MEN1LMNAKMT2A | |
| Choline SCHEMBL6017026 | 0.87 | SMN1; SMN2 (0.63) | SMN1; SMN2MEN1LMNAKMT2ACYP3A4 | |
| SCHEMBL30211934 | 0.85 | PGK1 (0.50) | SMN1; SMN2LPAR5PGK1PGK2LPAR1 | |
| SCHEMBL29822621 | 0.85 | PGK1 (0.50) | SMN1; SMN2LPAR5PGK1PGK2LPAR1 | |
| Choline SCHEMBL2733734 | 0.85 | SMN1; SMN2 (0.65) | SMN1; SMN2MEN1LMNAKMT2ACYP3A4 | |
| Choline SCHEMBL29922745 | 0.84 | SMN1; SMN2 (0.64) | SMN1; SMN2LPAR5MEN1LMNAKMT2A | |
| Glycerin SCHEMBL8890733 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2LPAR5PGK1PGK2LPAR1 | |
| Citric Acid SCHEMBL30874191 | 0.83 | SMN1; SMN2 (0.46) | SMN1; SMN2LPAR5PGK1PGK2LPAR1 | |
| SCHEMBL213379 | 0.83 | PGK1 (0.52) | SMN1; SMN2LPAR5LMNAPGK1PGK2 | |
| SCHEMBL6655023 | 0.83 | PGK1 (0.52) | SMN1; SMN2LPAR5LMNAPGK1PGK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118091155-A | Colorectal cancer metabolic marker and application thereof in diagnosis of colorectal cancer | 汕头大学医学院第二附属医院 | 2024-05-28 | — | — | CN | claimed |
| CN-111407721-B | System for promoting active ingredient to permeate skin | 复旦大学 | 2024-04-30 | — | — | CN | claimed |
| WO-2020029221-A1 | COMPOSITION WITH INHIBITING FAT FORMATION AND ANTIOXIDATIVE ACTIVITIES AND USE THEREOF | 黄福星 | 2020-02-13 | — | — | WO | claimed |
| CN-118091155-B | Colorectal cancer metabolic marker and application thereof in diagnosis of colorectal cancer | 汕头大学医学院第二附属医院 | 2025-02-18 | — | — | CN | disclosed |
| CN-118091155-A | Colorectal cancer metabolic marker and application thereof in diagnosis of colorectal cancer | 汕头大学医学院第二附属医院 | 2024-05-28 | — | — | CN | disclosed |
| CN-111407721-B | System for promoting active ingredient to permeate skin | 复旦大学 | 2024-04-30 | — | — | CN | disclosed |
| WO-2020029221-A1 | COMPOSITION WITH INHIBITING FAT FORMATION AND ANTIOXIDATIVE ACTIVITIES AND USE THEREOF | 黄福星 | 2020-02-13 | — | — | WO | disclosed |
| EP-2268263-A1 | IMPROVED TOPICAL OPHTHALMIC COMPOSITIONS | Bausch & Lomb Incorporated (US) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009120566-A1 | IMPROVED TOPICAL OPHTHALMIC COMPOSITIONS | BAUSCH & LOMB INCORPORATED (US) | 2009-10-01 | — | — | WO | disclosed |
| US-20090239836-A1 | Multifunctional Ophthalmic Compositions | PRECISION DERMATOLOGY, INC. | 2009-09-24 | — | — | US | disclosed |
| WO-2000023071-A9 | PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFLAMMATORY AND IMMUNE DISORDERS | LEUKOSITE INC (US) | 2000-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239836-A1 | Multifunctional Ophthalmic Compositions | UACA, NONO, PDE6C | SMN1; SMN2 781/4885LPAR5 1003/4885MEN1 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.